Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P855: Variable importance analysis based on gut microbiota and dietary factors between IBD patients and healthy controls in China

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Hu1,2, P. Wang3,4, X. Zhou5, A. Xiao6, N. You5, Y. Zhang2, M. Zhang2, M. Zheng2, S. Hutfless3,4, M. Zhi*2

1The Sixth Affiliated Hospital of Sun Yat-sen University, Guangdong Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, China, 2the Sixth Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China, 3Johns Hopkins University, Department of Medicine, Baltimore, MD, USA, 4Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, MD, USA, 5Sun Yat-Sen University, School of Mathematics and Computational Science, Guangzhou, China, 6Johns Hopkins University, Baltimore, MD, USA

P856: Compositional changes in the gut microbiota of Korean inflammatory bowel disease patients are linked to clinical phenotypes

ECCO '19 Copenhagen

Year: 2019
Authors:

C. H. Choi*1, Y. Kim1, S. Y. Shin1, K. Kim2, K-M. Lee3, S-A. Jung4, C. Serrano5, S. C. Lee5

1Chung-Ang University College of Medicine, Internal Medicine, Seoul, South Korea, 2Chung-Ang University College of Medicine, Microbiology, Seoul, South Korea, 3The Catholic University of Korea, St. Vincent’s Hospital, Internal Medicine, Suwon, South Korea, 4Ewha Womans University College of Medicine, Internal Medicine, Seoul, South Korea, 5South Texas Center of Emerging Infectious Diseases, Biology, San Antonio, USA

P857: The microbiota profile reflects disease severity in paediatric onset IBD

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Malham*1, B. Lilje2, K. Winther3, G. Houen2, P. S. Andersen2, C. Jakobsen1,4

1Hvidovre University Hospital, The Paediatric Department, Hvidovre, Denmark, 2Statens Serum Institut, The Department for Bacteria, Parasites and Fungi, Copenhagen, Denmark, 3Nordsjaellands Hospital, The Paediatric Department, Hilleroed, Denmark, 4Hvidovre University Hospital, The GastroUnit, Hvidovre, Denmark

P858: Impact of ileocaecal resection on gut microbiota in ileal Crohn’s disease patients

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Opstelten*1, F. Paganelli2, M. Bonten2, R. Willems2, B. Witteman3,4, H. Leavis5, B. Oldenburg1

1University Medical Center Utrecht, Department Gastroenterology and Hepatology, Utrecht, The Netherlands, 2University Medical Center Utrecht, Department Medical Microbiology, Utrecht, The Netherlands, 3Wageningen University, Division of Human Nutrition, Wageningen, The Netherlands, 4Hospital Gelderse Vallei, Department Gastroenterology and Hepatology, Ede, The Netherlands, 5University Medical Center Utrecht, Department Rheumatology and Clinical Immunology, Utrecht, The Netherlands

P859: Hepatitis E seroprevalence in Portuguese inflammatory bowel disease patients under immunosuppression is higher than expected

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Garrido*1, T. Guedes1, M. Abreu2, I. Pedroto1, P. Lago1

1Centro Hospitalar Universitário do Porto, Gastroenterology, Porto, Portugal, 2Centro Hospitalar Universitário do Porto, Infectious Diseases, Porto, Portugal

P860: Evaluation of the probiotic features of two different multi-strain probiotic preparations from two different manufacturers

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Colombo*1, V. Sagheddu2, M. Elli2, D. Mora3

1Beingpharma, Milan, Italy, 2AAT-Advanced Analytical Technologies Srl, Fiorenzuola d’Arda, Italy, 3Università degli studi di Milano, Defens, Milano, Italy

P861: Differences in bacteroidal genotypes between newly diagnosed ulcerative colitis patients and healthy controls

ECCO '19 Copenhagen

Year: 2019
Authors:

I. Baston*1, R. Sueiro2, C. Calviño1, D. De la Iglesia1, R. Ferreiro-Iglesias1, J. M. Leiro2, J. E. Dominguez-Munoz1, M. Barreiro-de Acosta1

1University Hospital, Gastroenterology, Santiago de Compostela, Spain, 2Department of Microbiology and Parasitology, University of Santiago de Compostela, Santiago de Compostela, Spain

DOP001: Effectiveness and safety of vedolizumab in anti-TNF naïve patients with inflammatory bowel disease: a multicentre retrospective European Crohn’s and Colitis Organisation studyECCO '18 Vienna
Year: 2018
Authors:

U. Kopylov1*, B. Verstockt2, L. Biedermann3, S. Sebastian4, D. Pugliese5, E. Sonnenberg6, P.R. Steinhagen6, N. Arebi7, Y. Ron8, T. Kucharzik9, X. Roblin10, B. Ungar1, A. Bar-Gil Shitrit11, S. Ardizzone12, P. Molander13, M. Coletta14, L. Peyrin-Biroulet15, P. Bossuyt16, I. Avni-Biron17, E.I. Tsoukal18, M. Allocca19, K. Katsanos20, T. Raine21, T. Sipponen22, G. Fiorino23, S. Ben-Horin1, R. Eliakim1, A. Armuzzi5, B. Siegmund6, D.C. Baumgart6, N. Kamperidis7, N. Maharshak8, C. Maaser9, G. Mantzaris18, H. Yanai17, D. Christodoulou20, I. Dotan17, M. Ferrante2

1Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 2KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3University of Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, 4Hull Royal Infirmary, Hull and East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, UK, 5IBD Unit, Complesso Integrato Columbus, Fondazione Policlinico Gemelli, Università Cattolica, internal Medicine, Gastroenterology Division, Rome, Italy, 6Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology and Medicine I, Berlin, Germany, 7LNWH ST MARKS HOSPITAL, Harrow, UK, 8Tel Aviv Medical Ceter, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, 9Hospital Lüneburg, Department of Internal Medicine and Gastroenterology, Lüneburg, Germany, 10CHU de Saint-Etienne, Gastroenterology, Saint-Etiennne, France, 11Shaare Zedek Medical Center, Digestive diseases Institute, Jerusalem, Israel, 12ASST Fatebenefratelli - Sacco, Milan, Italy, 13Helsinki University Central Hospital, Department of Gastroenterology, Department of Medicine, Helsinki, Finland, 14Department of Pathophysiology and Transplantation, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy, Gatroenterology, Milan, Italy, 15Nancy University Hospital, Université de Lorraine, Hepatogastroenterology, Vandoeuvre-lès-Nancy, France, 16Imelda GI Clinical Research Center, Gastroenterology, Bonheiden, Belgium, 17Rabin Medical Center, Department of Gastroenterology and Liver Diseases, Petach Tikva, Israel, 18Evaggelismos Hospital, Gastroenterology, Athens, Greece, 19Humanitas Gradenigo, Gastroenterology, Turin, Italy, 20University of Ioannina, Gastroenterology, Ioannina, Greece, 21Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology, Cambridge, UK, 22Helsinki University Central Hospital - Meilahti Hospital, Department of Gastroenterology, Helsinki, Finland, 23Humanitas Research Hospital, Department of Gastroenterology, IBD Center, Rozzano, Italy

DOP002: Vedolizumab treatment persistence up to 3 years: post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS studyECCO '18 Vienna
Year: 2018
Authors:

S. Vermeire1*, E.V. Loftus Jr.2, J.M. Khalid3, D. Tudor4, M. Akbari5, D. Demuth3, L. Peyrin-Biroulet6

1University Hospitals Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium, 2Mayo Clinic College of Medicine, Gastroenterology and Hepatology, Rochester, Minnesota, USA, 3Takeda Development Centre Europe Ltd., Evidence and Value Generation, London, UK, 4Takeda Pharmaceuticals International AG, Zurich, Switzerland, 5Takeda Pharmaceuticals International Co., Cambridge, Massachusetts, USA, 6Nancy University Hospital, Lorraine University, Department of Gastroenterology, Nancy, France

DOP003: Ustekinumab induces clinical and biological remission in biologic refractory Crohn’s disease patients: A real-world belgian cohort studyECCO '18 Vienna
Year: 2018
Authors:

C. Liefferinckx1,2*, B. Verstockt3, A. Gils4, M. Noman3, C. Van Kemseke5, E. Macken6, M. De Vos7, W. Van Moerkercke8, J.-F. Rahier9, P. Bossuyt10, J. Dutré11, E. Humblet12, D. Staessen13, H. Peeters14, P. Van Hootegem15, E. Louis5, D. Franchimont1,2, F. Baert16, S. Vermeire3

1Hopital Erasme, ULB, Department of Gastroenterology, Brussels, Belgium, 2Université libre de bruxelles, Laboratory of Experimental Gastroenterology, Brussels, Belgium, 3University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 4KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 5Centre Hospitalier Universitaire Sart-Tilman, ULG, Department of Gastroenterology, Liège, Belgium, 6Universiteit ziekenhuis Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, 7Universitair ziekenhuis Gent, Department of Gastroenterology, Gent, Belgium, 8AZ Groeninge, department of Gastroenterology, Kortrijk, Belgium, 9Centre Hospitalier Universitaire Mont-Godinne, UCL, Department of Gastroenterology, Yvoir, Belgium, 10Imeldaziekenhuis, Department of Gastroenterology, Bonheiden, Belgium, 11Ziekenhuis Netwerk Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, 12Ziekenhuis Oost-Limburg - Campus Sint-Jan, Department of Gastroenterology, Genk, Belgium, 13GZA Sint-Vincentius ziekenhuis, Department of Gastroenterology, Antwerpen, Belgium, 14Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Gent, Belgium, 15Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Brugge, Belgium, 16AZ Delta, Department of gastroenterology, Roeselare-Menen, Belgium

DOP004: Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACYECCO '18 Vienna
Year: 2018
Authors:

P. Bossuyt1*, R. Atreya2, C. Taxonera3,4, X. Hebuterne5,6, K. Isaacs7, P.D. Higgins8, J. Lindsay9, G. Heap10, D. Arikan10, V. Kuehnl11, J. Petersson10, A.M. Robinson10, E.V. Loftus Jr.12

1Imelda General Hospital, Bonheiden, Belgium, 2Friedrich-Alexander-University Erlangen-Nürnberg, Medical Clinic 1, Erlangen, Germany, 3Hospital Clínico San Carlos, Inflammatory Bowel Disease Unit, Department of Gastroenterology, Madrid, Spain, 4Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, 5Service de Gastroentérologie et Nutrition Clinique, Nice, France, 6Université de Nice-Sophia-Antipolis, Nice, France, 7University of North Carolina, Division of Gastroenterology and Hepatology, Chapel Hill, USA, 8University of Michigan, Ann Arbor, USA, 9Queen Mary University of London, Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, London, UK, 10AbbVie Inc., North Chicago, USA, 11AbbVie Deutschland GmbH and Co. KG, Ludwigshafen, Germany, 12Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, USA

DOP005: Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonistsECCO '18 Vienna
Year: 2018
Authors:

R. Cohen1, F. Bhayat2*, G. Hantsbarger2, A. Blake3, S. Vermeire4

1Inflammatory Bowel Disease Center, University of Chicago Medicine, Department of Medicine, Chicago, USA, 2Takeda Development Center Americas, Inc., Cambridge, USA, 3Takeda International - UK Branch, London, UK, 4University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium

DOP006: A multicentre cohort study to assess the safety of vedolizumab for inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

J. Meserve1, S. Aniwan2, J.L. Koliani-Pace3, P. Shashi4, A. Weiss5, D. Faleck6, A. Winters6, S. Chablaney6, G. Kochhar4, B. Boland1, S. Singh1, R. Hirten6, E. Shmidt6, M. Bohm7, S. V Sagi7, M. Fischer7, D. Lukin5, D. Hudesman8, S. Chang8, K. Sultan9, A. Swaminath10, N. Gupta11, S. Kane2, E.V. Loftus2, B. Shen4, B.E. Sands6, J.-F. Colombel6, C.A. Siegel3, W.J. Sandborn1, P.S. Dulai1*

1University of California - San Diego, La Jolla, USA, 2Mayo Clinic, Rochester, USA, 3Dartmouth-Hitchcock Medical Center, Lebanon, USA, 4Cleveland Clinic Foundation, Cleveland, USA, 5Montefiore Medical Center, New York, USA, 6Icahn School of Medicine at Mount Sinai, New York, USA, 7Indiana University, Indianapolis, USA, 8New York University (NYU), New York, USA, 9North Shore University Hospital, Manhasset, USA, 10Lenox Hill Hospital, New York, USA, 11University of Mississippi, Jackson, USA

DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

R. Bor1*, F. Klaudia2, P. Miheller3, K. Palatka4, T. Szamosi5, Á. Vincze6, M. Rutka7, K. Szántó2, A. Bálint2, Z. Szepes2, F. Nagy2, Á. Milassin2, A. Fábián2, Á. Csontos3, P. Golovics5, L. Lakner8, K. Müllner3, M. Papp9, Á. Salamon10, K. Sarang8, Z. Vitális4, E. Schafer11, P. Sarlós6, T. Molnár2

1University of Szeged, First Department of Medicine, Szaged, Hungary, 2University of Szeged, First Department of Medicine, Szeged, Hungary, 3Semmelweis University, 2nd Department of Medicine, Budapest, Hungary, 4University of Debrecen, 2nd Department of Medicine, Debrecen, Hungary, 5Hungarian Defence Force Military Hospital, Department of Gastroenterology, Budapest, Hungary, 6University of Pécs, 1st Department of Medicine, Pécs, Hungary, 7Uversity of Szeged, First Department of Medicine, Szeged, Hungary, 8Markusovszky Teaching Hospital, Szombathely, Hungary, 9University of Debrecen, 2nd Department of Medicine, Szeged, Hungary, 10Balassa János Hospital, Szekszárd, Hungary, 11Semmelweis University, 2nd Department of Medicine, Szeged, Hungary

DOP008: Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registryECCO '18 Vienna
Year: 2018
Authors:

D. Turner1*, S. Koletzko2, H. Winter3, R. Baldassano4, M. Dubinsky5, W. Faubion6, J. Hyams7, S. Kugathasan8, J. Rosh9, J. Escher10, A. Griffiths11, J. Kierkus12, R. Russell13, G. Heap14, D. Arikan14, V. Kuehnl15, J. Petersson14, A. Robinson16, F. Ruemmele17

1Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Jerusalem, Israel, 2Dr. von Hauner Children’s Hospital, University Medical Center, LMU Munich, Munich, Germany, 3Department of Pediatrics, Massachusetts General Hospital, Boston, USA, 4Pediatric Gastroenterology, The Children’s Hospital of Philadelphia, Philadelphia, USA, 5Department of Pediatrics, Division of Gastroenterology, Mount Sinai Medical Center, New York, USA, 6Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, USA, 7Division of Digestive Diseases, Connecticut Children’s Medical Center, Hartford, USA, 8Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, USA, 9Division of Gastroenterology and Nutrition, Goryeb Children’s Hospital, Morristown, USA, 10Erasmus Medical Center-Sophia Children’s Hospital, Rotterdam, The Netherlands, 11Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada, 12Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Children’s Memorial Health Institute, Warsaw, Poland, 13Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, UK, 14AbbVie Inc., North Chicago, USA, 15AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 16Abbvie, Inc., North Chicago, USA, 17Paediatric Gastroenterology, Hôpital Necker Enfants Malades, APHP, University Paris Descartes Sorbonne Paris Cité, Paris, France

DOP009: Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysisECCO '18 Vienna
Year: 2018
Authors:

D. Lukin1, A. Weiss1, S. Aniwan2, S. Kadire3, G. Tran3, M. Rahal3, D. Faleck4, A. Winters4, S. Chablaney4, J. Meserve5, G. Kochhar6, P. Shashi6, J.L. Koliani-Pace7, M. Bohm3, S.V. Sagi3, M. Fischer3, B. Boland5, S. Singh5, R. Hirten4, E. Shmidt4, D. Hudesman8, S. Chang8, K. Sultan9, A. Swaminath10, N. Gupta11, S. Kane2, E.V. Loftus2, B. Shen6, B.E. Sands4, W.J. Sandborn5, J.-F. Colombel4, C.A. Siegel7, P.S. Dulai5*

1Montefiore Medical Center, New York, USA, 2Mayo Clinic, Rochester, USA, 3Indiana University, Indianapolis, USA, 4Icahn School of Medicine at Mount Sinai, New York, USA, 5University of California - San Diego, La Jolla, USA, 6Cleveland Clinic Foundation, Cleveland, USA, 7Dartmouth-Hitchcock Medical Center, Lebanon, USA, 8New York University (NYU), New York, USA, 9North Shore University Hospital, Manhasset, USA, 10Lenox Hill Hospital, New York, USA, 11University of Mississippi, Jackson, USA

DOP010: Activating PIK3CD mutations cause severe intestinal lymphonodular hyperplasia and an IBD-like phenotypeECCO '18 Vienna
Year: 2018
Authors:

S. Farachi1, L. Werner2, L. Konnikova3, F. Rea1, I. Vardi4, E. Romeo1, O. Barel4, P. De Angelis1, L. Dall’Oglio1, G. Rechavi4, S. Snapper3, R. Somech2, B. Weiss5, C. Cancrini1, D. Shouval2*

1Bambino Gesù Children Hospital, Department of Endoscopy, Rome, Italy, 2Edmond and Lily Safra Children's Hospital, Pediatric Gastroenterology Unit, Tel Hashomer, Israel, 3Boston Children's Hospital, Boston, USA, 4Sheba Medical Center, Tel Hashomer, Israel, 5Edmond and Lily Safra Children's Hospital, Tel Hashomer, Israel

DOP011: Genotype–phenotype association analysis of inflammatory bowel disease in 6395 East Asian subjects: results from the international IBD Genetics ConsortiumECCO '18 Vienna
Year: 2018
Authors:

S. Abedian1*, S.H. Wong2, S. Van Sommeren3, A. Takahashi4, J.H. Cheon5, W.H. Kim5, K. Yamazaki6, S.-K. Yang7, M. Kubo6, R.K. Weersma3, B.Z. Alizadeh1, S.C. Ng2

1University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands, 2The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Faculty of Medicine, Hong Kong, China, 3University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands, 4Riken, Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, Yokohama, Japan, 5Yonsei University College of Medicine, Department of Gastroenterology and Hepatology, Seoul, South Korea, 6Riken, Laboratory for Genotyping Development, Center for Integrative Medical Sciences, Yokohama, Japan, 7Asan Medical Center, University of Ulsan College of Medicine, Department of Gastroenterology and Hepatology, Seoul, South Korea

DOP012: Disease demarcation in ulcerative colitis is associated with different patterns of gene expressionECCO '18 Vienna
Year: 2018
Authors:

M. Suarez-Farinas1, R. Huang1, R. Kosoy1, A. Irizar1, B. Losic1, G. Wei1, L. Peters1, W.-m. Song1, A. Di Narzo1, W. Wang1, J. Perrigoue2, A. Castillo3, J. Rogers3, A. Atreja3, A. Hurley1, M. Mahajan1, B. Zhang1, A. Stojmirovic2, M. Curran2, R. Dobrin2,4, M. Dubinsky3, K. Hao1, J. Zhu1, E. Schadt1, S. Plevy2, J. Friedman2, C. Brodmerkel2, B. Sands3, A. Kasarskis1, R. Ungaro3, C. Argmann1*, J.-F. Colombel3

1Icahn School of Medicine at Mount Sinai, Genetics and Genomics Sciences, New York, USA, 2Janssen R&D, Spring House, USA, 3Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, USA, 4Bristo-Myers Squibb, Hopewell, USA

DOP013: An IBD-associated variant in PTPN2 promotes inflammatory responses but enhances the anti-inflammatory effect of spermidineECCO '18 Vienna
Year: 2018
Authors:

M. Butter*, N. Obialo, K. Bäbler, L. Van der Lely, S. Lang, C. Gottier, M. Scharl, M.R. Spalinger

University Hospital of Zurich, University of Zurich, Clinic for Gastroenterology and Hepatology, Zurich, Switzerland